The financials
Revvity by the numbers
Revvity (RVTY) reported revenue of $730M in Q2 2026 (quarter ended July 5, 2026), up 1.3% from the same quarter a year earlier. That came with a gross margin of 57% and net income of $52M (7.1% of revenue). For the full year FY2025, revenue was $2.86B (+3.7% year on year) and net income $241M. Its largest segment in 2026-Q2 was Life Sciences at $184M, 56% of the disclosed total, just ahead of Diagnostics at 44%.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $730M | $720M | +1.3% |
| Gross profit | $417M | $393M | +6.2% |
| Operating income | $89M | $91M | −1.6% |
| Net income | $52M | $54M | −3.9% |
| Diluted EPS | $0.47 | $0.46 | +2.2% |
| Operating | Revenue | Share |
|---|---|---|
| Life Sciences | $184M | 56% |
| Diagnostics | $142M | 44% |
Business Segments
Revenue split by operating segment, from SEC XBRL filings.
Latest period: Q2 2026Total $325.6M (+3.0%)
Diagnostics grew +12% year on yearLife Sciences -6.8% year on year
Segment Latestquarter on quarteryear on year
- Life Sciences$183.6M$183.6MQoQ -1.1%year on year -6.8%-1.1%-6.8%
- Diagnostics$142.0M$142.0MQoQ +8.9%year on year +12%+8.9%+12%
Diagnostics & Research
Ranks #26 of 29 by Smart Score